ALGESTONE ACETOPHENIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H36O4
Molecular Weight	448.5937
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1(O[C@@](C)(O2)C6=CC=CC=C6)C(C)=O

InChI

InChIKey=AHBKIEXBQNRDNL-FVCOMRFXSA-N

InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C29H36O4
Molecular Weight	448.5937
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5661206 | https://www.ncbi.nlm.nih.gov/pubmed/12290848

Algestone acetophenide, also known as dihydroxyprogesterone acetophenide, is an agonist of the progesterone receptor. Algestone acetophenide in combination with estradiol enanthate is sold under the brand name Deladroxate as a form of long-lasting injectable birth control. The combination provides simultaneously prolonged progestational and estrogenic activities both of which are maintained at effective levels for approximately three weeks after the intramuscular injection of a single dose.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pregnancy 65 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5661206 https://www.ncbi.nlm.nih.gov/pubmed/12290848	Preventing		Approved 8429	Deladroxate Approved Use Combined Injectable Contraceptive

PubMed

Title	Date	PubMed
OVULATION INHIBITION WITH A LONG-ACTING PARENTERAL PROGESTOGEN-ESTROGEN COMBINATION.	1964 Nov-Dec	14236842
DELADROXATE FOR THE PREVENTION OF OVULATION.	1964 Nov-Dec	14236841
Deladroxate: a one-a-month intramuscular contraceptive.	1968 Jul	5661206
A review of "once-a-month" combined injectable contraceptives.	1994	12290848

Sample Use Guides

In Vivo Use Guide

On the eight day (7th-9th) after the onset of menstruation from the last ovulatory cycle, one ml.of Deladroxate (150 mg of dihydroxyprogesterone acetophenide combined with 10 mg of estradiol enanthate) was injected intramuscularly in the deltoid or gluteal region.

Route of Administration: Intramuscular

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:05:33 GMT 2023` Edited by `admin` on `Fri Dec 15 15:05:33 GMT 2023`
Record UNII	OL7KC2O3OT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALGESTONE ACETOPHENIDE

Official Name

English

ALGESTONE ACETOPHENIDE [MART.]

Common Name

English

Algestone acetophenide [WHO-DD]

Common Name

English

PREGN-4-ENE-3,20-DIONE, 16,17-((1-PHENYLETHYLIDENE)BIS(OXY))-, (16.ALPHA.(R))-

Common Name

English

SQ 15,101

Code

English

ALGESTONE ACETOPHENIDE [USAN]

Common Name

English

ALGESTONE ACETOPHENIDE [MI]

Common Name

English

(R)-16α,17-Dihydroxypregn-4-ene-3,20-dione cyclic acetal with acetophenone

Common Name

English

DELADROXONE

Brand Name

English

NSC-759863

Code

English

SQ-15101

Code

English

SO-15101

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C776